Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313541" target="_blank" >RIV/00216208:11110/15:10313541 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1159/000431336" target="_blank" >http://dx.doi.org/10.1159/000431336</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000431336" target="_blank" >10.1159/000431336</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab

Popis výsledku v původním jazyce

Background/Aims: Rituximab and glucocorticoids are a non-inferior alternative to cyclophosphamide and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) patients with moderate renaldisease. The efficacy and safety of this approach in patients with severe renal impairment are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in patients with AAV and ANCA-negative vasculitis presenting with severe renal disease. Methods: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. Patients with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of <= 20 ml/min/ 1.73 m(2)treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen patients met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The second

Název v anglickém jazyce

Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab

Popis výsledku anglicky

Background/Aims: Rituximab and glucocorticoids are a non-inferior alternative to cyclophosphamide and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) patients with moderate renaldisease. The efficacy and safety of this approach in patients with severe renal impairment are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in patients with AAV and ANCA-negative vasculitis presenting with severe renal disease. Methods: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. Patients with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of <= 20 ml/min/ 1.73 m(2)treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen patients met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The second

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Nephrology

ISSN

0250-8095

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

4-5

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

6

Strana od-do

296-301

Kód UT WoS článku

000358515000005

EID výsledku v databázi Scopus

2-s2.0-84930532045